Replies to post #92760 on Biotech Values

[flatlander_60048]

Teva indicates it is more concerned about new oral treatments entering the MS market. Either way I think NVS is positioned to challenge Copaxone.

How do you handicap the odds that FTY720 gets approved in 2010.

FL